PET/CT evaluation of 18F-FDG uptake in pericoronary adipose tissue in patients with stable coronary artery disease: Independent predictor of atherosclerotic lesions' formation? | springermedicine.com

Springer Medicine

Top

Journal of Nuclear Cardiology

Published in:

01-06-2017 | Original Article

PET/CT evaluation of ¹⁸F-FDG uptake in pericoronary adipose tissue in patients with stable coronary artery disease: Independent predictor of atherosclerotic lesions' formation?

Authors: Tomasz Mazurek, MD, PhD, Małgorzata Kobylecka, MD, PhD, Magdalena Zielenkiewicz, MSc, Aleksandra Kurek, BSc, Janusz Kochman, MD, PhD, Krzysztof J. Filipiak, MD, PhD, FESC, Krzysztof Mazurek, MD, PhD, Zenon Huczek, MD, PhD, Leszek Królicki, MD, PhD, Grzegorz Opolski, MD, PhD, FESC

Published in: Journal of Nuclear Cardiology | Issue 3/2017

Login to get access

Abstract

Background

Inflammatory infiltrations in EAT which releases inflammatory cytokines correspond anatomically to the atheromatous plaques in underlying coronary vessels. However, it is unknown whether inflammatory activity of pericoronary adipose tissue (PCAT) promotes coronary atherosclerosis.

Methods and Results

35 non-diabetic patients with confirmed CAD and 35 non-CAD controls matched for age and BMI underwent 18F-FDG-PET/CT. Maximal SUV normalized by LA blood activity was measured on the sections corresponding to the respective coronaries (RCA, LCX, LAD), as well, as in subcutaneous fat, visceral fat, and epicardial fat. Extent of CAD was determined by % stenosis in segments corresponding to 18F-FDG-PET/CT sections in coronarography using quantitative coronary analysis. PCAT SUV was significantly greater than SUV in other fat locations, as well as PCAT SUV in the controls. In CAD patients with BMI >25, PCAT SUV was positively related to % stenosis of a respective coronary artery (RCA: 0.43; P < .05; LCX 0.58; P < .05; LAD 0.65; P < .05). PCAT SUV was the only independent predictor of coronary stenosis of LAD and RCA.

Conclusions

Inflammatory activity of PCAT is greater than in other fat locations, in CAD is greater than in non-CAD controls, and is independently associated with coronary stenosis. In overweight patients, PCAT SUV correlates with the extent of CAD.

1.

Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:2045-51.CrossRefPubMedPubMedCentral

2.

Zhang L, Zalewski A, Liu Y, Mazurek T, Cowan S, Martin JL, et al. Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation 2003;108:472-8.CrossRefPubMed

3.

Yudkin JS, Eringa E, Stehouwer CDA. “Vasocrine” signaling from perivascular fat: A mechanism linking insulin resistance to vascular disease. Lancet 2005;365:1817-20.CrossRefPubMed

4.

Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004;145:2273-82.CrossRefPubMed

5.

Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003;108:2460-6.CrossRefPubMed

6.

Gorter PM, van Lindert AS, de Vos AM, Meijs MF, van der Graaf Y, Doevendans PA, et al. Quantification of epicardial and peri-coronary fat using cardiac computed tomography; reproducibility and relation with obesity and metabolic syndrome in patients suspected of coronary artery disease. Atherosclerosis 2008;197:896-903.CrossRefPubMed

7.

Iacobellis G, Willens HJ, Barbaro G, Sharma AM. Threshold values of high-risk echocardiographic epicardial fat thickness. Obesity 2008;16:887-92.CrossRefPubMed

8.

Fox CS, Gona P, Hoffmann U, Porter SA, Salton CJ, Massaro JM, et al. Pericardial fat, intrathoracic fat, and measures of left ventricular structure and function. The Framingham heart study. Circulation 2009;119:1586-91.CrossRefPubMedPubMedCentral

9.

Mazurek T. Proinflammatory capacity of adipose tissue: New insights in the pathophysiology of atherosclerosis. Kardiol Pol 2009;67(10):1119-24.PubMed

10.

Mazurek T, Opolski G. Pericoronary adipose tissue: A novel therapeutic target in obesity-related coronary atherosclerosis. J Am Coll Nutr 2015;34(3):244-54.CrossRefPubMed

11.

Aziz K, Berger K, Claycombe K, Huang R, Patel R, Abela GS. Noninvasive detection and localization of vulnerable plaque and arterial thrombosis with computed tomography angiography/positron emission tomography. Circulation 2008;117:2061-70.CrossRefPubMed

12.

Bucerius J, Mani V, Moncrieff C, Machac J, Fuster V, Farkouh ME, et al. Optimizing (18)F-FDG PET/CT imaging of vessel wall inflammation: The impact of (18)F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels. Eur J Nucl Med 2014;41:369-83.CrossRef

13.

Mazurek T, Kiliszek M, Kobylecka M, Kochman J, Filipiak K, Królicki L, et al. Proinflammatory activity of epicardial adipose tissue may affect the occurrence of atrial fibrillation. Am J Cardiol 2014;113:1505-8.CrossRefPubMed

14.

Mazurek T, Kochman J, Kobylecka M, Wilimski R, Filipiak K, Królicki L, et al. Inflammatory activity of pericoronary adipose tissue may affect plaque composition in patients with acute coronary syndrome without persistent ST-segment elevation: Preliminary results. Kardiol Pol 2014;72:410-6.CrossRefPubMed

15.

Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: A prospective clinical trial. Lancet 2013;S0140-6736:61754-7.

16.

Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Ann Intern Med 2013;159:758-69.CrossRefPubMed

17.

Karastergiou K, Evans I, Ogston N, Miheisi N, Nair D, Kaski JC, et al. Epicardial adipokines in obesity and coronary artery disease induce atherogenic changes in monocytes and endothelial cells. Arterioscler Thromb Vasc Biol 2010;30:1340-6.CrossRefPubMed

18.

Bigornia SJ, Farb MG, Mott MM, Hess DT, Carmine B, Fiscale A, et al. Relation of depot-specific adipose inflammation to insulin resistance in human obesity. Nutr Diabetes 2012;2:1-6.CrossRef

19.

Weikert C, Westphal S, Berger K, Dierkes J, Mohling M, Spranger J, et al. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 2008;93:2647-53.CrossRefPubMed

20.

Cheng VY, Dey D, Tamarappoo B, Nakazato R, Gransar H, Miranda-Peats R, et al. Pericardial fat burden on ECG-gated noncontrast CT in asymptomatic patients who subsequently experience adverse cardiovascular events. J Am Coll Cardiol Imaging 2010;3:352-60.CrossRef

21.

Chen O, Sharma A, Ahmad I, Bourji N, Nestoiter K, Hua P, et al. Correlation between pericardial, mediastinal, and intrathoracic fat volumes with the presence and severity of coronary artery disease, metabolic syndrome, and cardiac risk factors. Eur Heart J Cardiovasc Imaging 2015;16:37-46.CrossRefPubMed

22.

Mahabadi AA, Lehmann N, Kälsch H, Robens T, Bauer M, Dykun I, et al. Association of epicardial adipose tissue with progression of coronary artery calcification is more pronounced in the early phase of atherosclerosis. Results from the Heinz Nixdorf Recall Study. J Am Coll Cardiol Imaging 2014;9:909-16.CrossRef

23.

Tawakol A, Singh P, Rudd JHF, Soffer J, Cai G, Vucic E, et al. Effect of treatment for 12 weeks with Rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-PET imaging. J Am Coll Cardiol 2014;63:86-8.CrossRefPubMed

24.

Mäki-Petäjä KM, Elkhawad M, Cheriyan J, Joshi FR, Ostor AJK, Hall FC, et al. Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 2012;126:2473-80.CrossRefPubMed

25.

Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: Results of a multi-center FDG-PET/CT feasibility study. J Am Coll Cardiol 2013;62:909-17.CrossRefPubMed

26.

Elkhawad M, Rudd JH, Sarov-Blat L, Cai G, Wells R, Davies LC, et al. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis. J Am Coll Cardiol Imaging 2012;5:911-22.CrossRef

Title: PET/CT evaluation of 18F-FDG uptake in pericoronary adipose tissue in patients with stable coronary artery disease: Independent predictor of atherosclerotic lesions' formation?
Authors: Tomasz Mazurek, MD, PhD
Małgorzata Kobylecka, MD, PhD
Magdalena Zielenkiewicz, MSc
Aleksandra Kurek, BSc
Janusz Kochman, MD, PhD
Krzysztof J. Filipiak, MD, PhD, FESC
Krzysztof Mazurek, MD, PhD
Zenon Huczek, MD, PhD
Leszek Królicki, MD, PhD
Grzegorz Opolski, MD, PhD, FESC
Publication date: 01-06-2017
Publisher: Springer US
Published in: Journal of Nuclear Cardiology / Issue 3/2017
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-015-0370-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties